台灣臨床試驗主持人資料庫|TPIDB

2016-03-01 - 2023-10-31

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
10Sites

Terminated8Sites

賴建志

Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-08-15 - 2023-11-30

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated6Sites

賴建志

Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2015-11-30 - 2026-05-31

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
9Sites

Terminated9Sites

黃煦晴

Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-11-01 - 2026-12-31

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated5Sites

黃書彬

Kaohsiung Municipal Gangshan Hospital

未分科

林永昌

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-11-01 - 2021-05-20

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
11Sites

Terminated9Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-05-01 - 2020-12-31

Phase II

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Terminated5Sites

白禮源

China Medical University Hospital-Taipei

未分科

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-09-01 - 2023-04-30

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

陳訓徹

Linkou Chang Gung Medical Foundation

Division of General Surgery

2015-07-01 - 2020-12-31

Phase II

Multicenter, open-label, single arm, Phase II study in advanced non-small cell lung cancer；Subtitle:A multicenter, open-label, single arm Phase II study to evaluate safety and efficacy of ONO-4538 in stage IIIB/IV or recurrent non-small cell lung cancer patients who are unsuited to radical radiotherapy and resistant to a platinum-base chemotherapeutic regimen.

Condition/Disease

stage IIIB/IV or recurrent non-small cell lung cancer
Test Drug

Opdivo®

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2017-02-01 - 2019-04-30

Phase III

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Condition/Disease

High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD)
Test Drug

RVX000222

Participate Sites
14Sites

Terminated14Sites

江晨恩

Taipei Veterans General Hospital

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2016-12-01 - 2018-06-30

Phase III

An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

Condition/Disease

Treatment-resistant Depression
Test Drug

ESKETAMINE

Participate Sites
8Sites

Terminated8Sites

李信謙

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Psychiatry

劉嘉逸

Linkou Chang Gung Medical Foundation

Division of Psychiatry

Search Result

List